Revenue Breakdown
Composition ()
No data
Revenue Streams
MiMedx Group Inc (MDXG) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Advanced Wound Care, accounting for 67.8% of total sales, equivalent to $77.10M. Another important revenue stream is Surgical. Understanding this composition is critical for investors evaluating how MDXG navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, MiMedx Group Inc maintains a gross margin of 70.05%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -27.21%, while the net margin is -18.41%. These profitability ratios, combined with a Return on Equity (ROE) of 13.77%, provide a clear picture of how effectively MDXG converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, MDXG competes directly with industry leaders such as EMBC and CERS. With a market capitalization of $530.25M, it holds a leading position in the sector. When comparing efficiency, MDXG's gross margin of 70.05% stands against EMBC's 56.45% and CERS's 56.98%. Such benchmarking helps identify whether MiMedx Group Inc is trading at a premium or discount relative to its financial performance.
